CAIRO5: FOLFOXIRI + Bevacizumab vs FOLFOX/FOLFIRI + Bevacizumab in Patients With Initially Unresectable Colorectal Liver Metastases and Right-Sided and/or RAS/BRAFV600E-Mutated Primary Tumors

June 3-7, 2022; Chicago, Illinois
Among patients with initially unresectable colorectal liver metastases and right-sided and/or RAS/BRAFV600E-mutated primary tumors, FOLFOXIRI + bevacizumab was associated with superior outcomes vs FOLFOX or FOLFIRI + bevacizumab with an increase in manageable toxicity.
Format: Microsoft PowerPoint (.ppt)
File Size: 141 KB
Released: June 10, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bristol-Myers Squibb
Daiichi Sankyo, Inc.

Related Content

Downloadable clinical resource with practical guidance on preventative care plans for transgender patients, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: October 7, 2022

Expert analysis module on key data from ESMO World GI 2022 in gastrointestinal cancers, from Clinical Care Options (CCO)

Joleen Hubbard, MD Rachna Shroff, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: October 4, 2022 Expired: October 3, 2023

An expert nurse practitioner provides guidance on strategies for developing compassionate care plans with transgender patients based on their current anatomy

person default Lauren Radziejewski, DNP Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: October 4, 2022 Expired: October 3, 2023

Download this expert slideset on strategies for developing compassionate care plans with transgender patients based on their current anatomy

person default Lauren Radziejewski, DNP Released: October 4, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings